ProCE Banner Activity

Expert Guidance on Optimizing Treatment Strategies for Acute Lymphoblastic Leukemia

Text Module
Amir T. Fathi, MD, reviews patient cases and the most recent clinical data to provide guidance on optimizing care for acute lymphoblastic leukemia using newer immunotherapy approaches.

Released: April 16, 2020

Expiration: April 15, 2021

No longer available for credit.

Share

Faculty

Amir Fathi

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Jazz Pharmaceuticals Inc

Pfizer, Inc.

Learning Objectives

  • Understand the data that establish the prognostic value of MRD assessment, primary methods for assessment, and the utilization of MRD assessment in the management of ALL at optimal stages of the disease process to improve patient outcomes
  • Apply clinical evidence and expert recommendations to select induction and postremission strategies for specific patient populations, including MRD-directed therapy for patients who are MRD positive
  • Evaluate the available evidence to optimally integrate BiTE antibodies, antibody–drug conjugates, engineered CAR T-cells, and other immune-based therapies in ALL
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with relapsed/refractory ALL, considering the available clinical evidence and new drug approvals
  • Discuss how to effectively sequence treatment with novel immunotherapies in ALL
  • Plan management strategies for treatment-related toxicities associated with novel therapeutics in ALL, including veno-occlusive disease, cytokine-release syndrome, and neurotoxicity
  • Design optimal treatment strategies for patients with Ph-positive and Ph-like ALL, including third-generation TKIs and pediatric-inspired regimens
  • Identify patients with ALL who may benefit from enrollment on clinical trials evaluating novel immune-based combination therapies

Faculty Disclosure

Primary Author

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Amir T. Fathi, MD, has disclosed that he has received research support from Agios, Celgene, and Takeda; has received consulting fees from Agios, Astellas, Celgene, Daiichi Sankyo, and Forty Seven; and has served on advisory boards for Amphivena, Jazz Pharmaceuticals, NewLink Genetics, Pfizer, and PTC Therapeutics.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Anna Poppa,

Managing Editor, HIV
Clinical Care Options, LLC

Anna Poppa has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.